These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36440057)

  • 1. Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma.
    Arafa M; Shebl AM; Salama A; ElZahaf E; Ashamallah SA; Foda AA; Awad AE; Shalaby A
    Eur J Obstet Gynecol Reprod Biol X; 2022 Dec; 16():100172. PubMed ID: 36440057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
    Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of PD-L1, VISTA, LAG-3, and GAL-3 Expressions and Their Relationships to Mismatch Repair Protein and p53 Expression in 529 Cases of Endometrial Carcinoma.
    Arslan-Kahraman DI; Ogut B; Inan MA; Kazanci F; Onan MA; Erdem M; Erdem O
    Int J Gynecol Pathol; 2024 Jun; ():. PubMed ID: 38914021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Characteristics and Prognosis of PD-L1-Positive Endometrial Carcinomas: A Retrospective Chart Review.
    Amarin JZ; Mansour R; Al-Ghnimat S; Al-Hussaini M
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer.
    Kim J; Kong JK; Yang W; Cho H; Chay DB; Lee BH; Cho SJ; Hong S; Kim JH
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PD-1/PD-L1-mediated tumour immune escape mechanism and microsatellite instability in the BCG failure of high-grade urothelial carcinomas.
    Salman FG; Kankaya D; Özakıncı H; Şahin Y; Kubilay E; Süer E; Hayme S; Baltacı S
    Turk J Med Sci; 2022 Dec; 52(6):1802-1813. PubMed ID: 36945968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
    Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India.
    Jain E; Prasad S; Dhar A; Kini L; Sharma S; Dewan A
    Pathologica; 2021 Apr; 113(2):115-120. PubMed ID: 34042092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.
    Yamashita H; Nakayama K; Ishikawa M; Nakamura K; Ishibashi T; Sanuki K; Ono R; Sasamori H; Minamoto T; Iida K; Sultana R; Ishikawa N; Kyo S
    Oncotarget; 2018 Jan; 9(5):5652-5664. PubMed ID: 29464025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma.
    Jiang D; Song Q; Wei X; Yu Z; Liu Y; Wang H; Wang X; Huang J; Su J; Hong Y; Xu Y; Xu C; Hou Y
    Front Oncol; 2022; 12():897527. PubMed ID: 35865481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 20. Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.
    Bulutay P; Eren ÖC; Özen Ö; Haberal AN; Kapucuoğlu N
    Turk J Obstet Gynecol; 2023 Sep; 20(3):164-173. PubMed ID: 37667475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.